Poor potential coverage for 7-valent pneumococcal conjugate vaccine, Malawi

Emerg Infect Dis. 2003 Jun;9(6):747-9. doi: 10.3201/eid0906.030020.

Abstract

Streptococcus pneumoniae infections can be prevented by using new conjugate vaccines, but these vaccines have limited serogroup coverage. We report the first serogrouping data from carried and invasive isolates obtained from children and adults in Malawi. The 7-valent vaccine would cover 41% of invasive isolates from children and 25% from adults. A 9-valent vaccine, including types 1 and 5, would cover 66% of invasive isolates from children and 55% from adults.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Carrier State
  • Child
  • Heptavalent Pneumococcal Conjugate Vaccine
  • Humans
  • Malawi / epidemiology
  • Meningococcal Vaccines* / immunology
  • Meningococcal Vaccines* / therapeutic use
  • Nasopharynx / microbiology
  • Pneumococcal Infections / epidemiology
  • Pneumococcal Infections / immunology
  • Pneumococcal Infections / prevention & control*
  • Pneumococcal Vaccines* / immunology
  • Pneumococcal Vaccines* / therapeutic use
  • Population Surveillance
  • Serotyping
  • Streptococcus pneumoniae / classification*
  • Streptococcus pneumoniae / immunology
  • Streptococcus pneumoniae / isolation & purification

Substances

  • Heptavalent Pneumococcal Conjugate Vaccine
  • Meningococcal Vaccines
  • Pneumococcal Vaccines